Document is current
Any future updates will be listed below
-
Authors
Lee, Chang Hwan
Lee, Yong Yook
Jung, Jin Sun
Hyun, Sun Hee
Lee, Jaehoon
Park, Ji-Hye
Park, Soo Kyung
Lee, Seung Ho
- License Information
-
More Information
Article History
Received: 25 April 2025
Accepted: 11 August 2025
First Online: 20 August 2025
Declarations
:
: The authors declare the following competing interests: C.H.L., Y.Y.L., S.H.H., and S.H.L. have filed an institution-owned patent entitled “A Composition for Preventing or Treating Dyslipidemia with the Effect of Inhibiting PCSK9 Expression” (Patent No. 10-2023-0194713), related to the development of KRG for hyperlipidemia treatment. No other authors declare any competing interests.
: The procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the Korea Ginseng Corporation (Approval Nos. KGC-2015-008, KGC-2023-014, and KGC-2023-020). The experiments were conducted following institutional guidelines and the principles outlined in the ARRIVE 2.0 guidelines to ensure transparency, reproducibility, and adherence to ethical standards in animal research.
